PVI
IMVT icon

Pura Vida Investments’s Immunovant IMVT Stock Holding History

Pura Vida Investments’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-118,702
Closed -$5.48M – 234
2020
Q4 		$5.48M Sell
118,702
-40,324
-25% -$1.86M 0.2% 102
2020
Q3 		$5.6M Sell
159,026
-111,780
-41% -$3.36M 0.29% 67
2020
Q2 		$6.59M Buy
+270,806
New +$5.8M 0.63% 39

Other funds holding IMVT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Pura Vida Investments's IMVT Position: Q1 2021 in Review

Pura Vida Investments sold out of Immunovant (IMVT) in Q1 2021, closing a stake of 118,702 shares — an estimated $5.48M sold.

Pura Vida Investments first reported a position in IMVT in Q2 2020 and held it in 3 quarters. The position peaked at $6.59M in Q2 2020. 120 funds tracked by Wall St. Rank hold IMVT as of Q1 2021.

  • Pura Vida Investments reported no remaining Immunovant position as of Q1 2021 after selling out during the quarter.
  • Pura Vida Investments sold 118,702 Immunovant shares in Q1 2021, an estimated $5.48M.
  • Pura Vida Investments first reported a position in Immunovant in Q2 2020 and held it in 3 quarters.
  • Pura Vida Investments's Immunovant position peaked at $6.59M in Q2 2020.
  • 120 funds tracked by Wall St. Rank held Immunovant as of Q1 2021.

Based on Pura Vida Investments's 13F filing for Q1 2021, filed 12 May 2021.